Evidence map›Paper›PMID 34725333›Full record

ArticleCell discovery2021

Multiomics interrogation into HBV (Hepatitis B virus)-host interaction reveals novel coding potential in human genome, and identifies canonical and non-canonical proteins as host restriction factors against HBV.

Shilin Yuan, Guanghong Liao, Menghuan Zhang, Yuanfei Zhu, Weidi Xiao, Kun Wang, Chuanyin Li, Caiwei Jia, Na Sun, Axel Walch and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cell discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Progress of Infection and Replication Systems of Hepatitis B Virus.ACS pharmacology & translational science · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. The sirtuin family in health and disease.Signal transduction and targeted therapy · 2022
    Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Shilin Yuan *Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Guanghong Liao *State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.
Menghuan Zhang *State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.
Yuanfei Zhu *Key Laboratory of Medical Molecular Virology (MOE & MOH), School of Basic Medical Sciences, Fudan University, Shanghai, China.
Weidi Xiao *State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Research Unit of Proteomics & Research and Development of New Drug of Chinese Academy of Medical Sciences, Beijing Institute of Lifeomics, Beijing, China.
Kun WangCancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Chuanyin LiCancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Caiwei JiaCancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Na SunResearch Unit Analytical Pathology, Helmholtz Zentrum München, Neuherberg, Germany.
Axel WalchResearch Unit Analytical Pathology, Helmholtz Zentrum München, Neuherberg, Germany.
Daming GaoState Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.
Ping XuState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Research Unit of Proteomics & Research and Development of New Drug of Chinese Academy of Medical Sciences, Beijing Institute of Lifeomics, Beijing, China. xuping_bprc@126.com.
Qiang DengKey Laboratory of Medical Molecular Virology (MOE & MOH), School of Basic Medical Sciences, Fudan University, Shanghai, China. qdeng@fudan.edu.cn.
Jian ZhangKey Laboratory of Cell Differentiation and Apoptosis, Medicinal Bioinformatics Center, Shanghai JiaoTong University School of Medicine, Shanghai, China. jian.zhang@sjtu.edu.cn.
He WangInstitute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China. hewang@fudan.edu.cn.
Ronggui HuCancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. coryhu@sibcb.ac.cn.ORCID http://orcid.org/0000-0001-8323-239X
Tongji University · CNChinese Academy of Sciences · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFudan University · CNHelmholtz Zentrum München · DEShanghai Jiao Tong University · CNShanghai Medical College of Fudan University · CNZhejiang Academy of Social Sciences · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81525019
6 · The paper itself

Abstract

Hepatitis B Virus (HBV) constitutes a major threat to global public health. Current understanding of HBV-host interaction is yet limited. Here, ribosome profiling, quantitative mass spectrometry and RNA-sequencing were conducted on a recently established HBV replication system, through which we identified multiomic differentially expressed genes (DEGs) that HBV orchestrated to remodel host proteostasis networks. Our multiomics interrogation revealed that HBV induced significant changes in both transcription and translation of 35 canonical genes including PPP1R15A, PGAM5 and SIRT6, as well as the expression of at least 15 non-canonical open reading frames (ncORFs) including ncPON2 and ncGRWD1, thus revealing an extra coding potential of human genome. Overexpression of these five genes but not the enzymatically deficient SIRT6 mutants suppressed HBV replication while knockdown of SIRT6 had opposite effect. Furthermore, the expression of SIRT6 was down-regulated in patients, cells or animal models of HBV infection. Mechanistic study further indicated that SIRT6 directly binds to mini-chromosome and deacetylates histone H3 lysine 9 (H3K9ac) and histone H3 lysine 56 (H3K56ac), and chemical activation of endogenous SIRT6 with MDL800 suppressed HBV infection in vitro and in vivo. By generating the first multiomics landscape of host-HBV interaction, our work is thus opening a new avenue to facilitate therapeutic development against HBV infection.

Identifiers

PMID34725333
PMCPMC8560872
OpenAlexW3210685717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.